

# Andreas Pinter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3032116/publications.pdf>

Version: 2024-02-01

41  
papers

2,046  
citations

471509

17  
h-index

289244

40  
g-index

42  
all docs

42  
docs citations

42  
times ranked

2069  
citing authors

#	ARTICLE	IF	CITATIONS
1	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. Journal of the American Academy of Dermatology, 2015, 73, 400-409.	1.2	472
2	Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS-3). Journal of the American Academy of Dermatology, 2017, 177, 1401-1409.	1.5	301
3	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. Journal of the American Academy of Dermatology, 2017, 76, 60-69.e9.	1.2	258
4	Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. Journal of Allergy and Clinical Immunology, 2020, 145, 173-182.	2.9	183
5	Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks. Journal of Investigative Dermatology, 2019, 139, 1054-1062.	0.7	150
6	Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (EXCEED). Journal of the American Academy of Dermatology, 2020, 82, 1070-1079.	1.0	170
7	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blind trial*. British Journal of Dermatology, 2021, 184, 1047-1058.	1.5	58
8	Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 533-541.	2.4	47
9	The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study. Journal of the American Academy of Dermatology, 2021, 85, 369-378.	1.2	46
10	The histone deacetylase inhibitor trichostatin A decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways. BMC Cancer, 2016, 16, 763.	2.6	33
11	Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI-16) analysis of randomized phase 2B study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1562-1568.	2.4	33
12	Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VEGF-cadherin-dependent mechanism. Experimental Dermatology, 2017, 26, 194-201.	2.9	32
13	A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. British Journal of Dermatology, 2020, 182, 869-879.	1.5	31
14	Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis. Journal of Dermatological Treatment, 2020, 31, 769-775.	2.2	31
15	Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). British Journal of Dermatology, 2020, 183, 265-275.	1.5	24
16	Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker – a retrospective multicenter study. Journal of Dermatological Treatment, 2021, 32, 878-882.	2.2	24
17	Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial*. British Journal of Dermatology, 2022, 186, 942-954.	1.5	22
18	A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 228-236.	2.4	21

#	ARTICLE	IF	CITATIONS
19	Adiponectin levels in a large pooled plaque psoriasis study population. <i>Journal of Dermatological Treatment</i> , 2020, 31, 531-534.	2.2	17
20	Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 533.	4.1	17
21	Interleukin-17 receptor blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases. <i>Journal of Dermatology</i> , 2019, 46, 426-430.	1.2	15
22	Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 2087-2100.	2.4	15
23	A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 701-711.	2.4	13
24	Dimethylfumarate effectively inhibits lymphangiogenesis via p21 induction and G1 cell cycle arrest. <i>Experimental Dermatology</i> , 2016, 25, 200-205.	2.9	12
25	Hidradenitis Suppurativa and Concurrent Psoriasis: Comparison of Epidemiology, Comorbidity Profiles, and Risk Factors. <i>Dermatology and Therapy</i> , 2020, 10, 721-734.	3.0	12
26	Reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1686-1691.	2.4	12
27	ERAPSO: Revealing the High Burden of Obesity in German Psoriasis Patients. <i>Dermatology and Therapy</i> , 2019, 9, 579-587.	3.0	11
28	Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 855-865.	2.4	11
29	Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2018, Volume 11, 451-459.	1.8	10
30	Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2022, 186, 30-39.	1.5	9
31	Mechanism of anti-inflammatory effects of rifampicin in an ex vivo culture system of hidradenitis suppurativa. <i>Experimental Dermatology</i> , 2022, 31, 1005-1013.	2.9	8
32	mTORC1 – a potential player in the pathogenesis of hidradenitis suppurativa?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e444-e447.	2.4	7
33	Biologic Treatment in Combination with Lifestyle Intervention in Moderate to Severe Plaque Psoriasis and Concomitant Metabolic Syndrome: Rationale and Methodology of the METABOLyx Randomized Controlled Clinical Trial. <i>Nutrients</i> , 2021, 13, 3015.	4.1	7
34	Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study. <i>Dermatology and Therapy</i> , 2022, 12, 561-575.	3.0	7
35	Management of Paediatric Psoriasis by Paediatricians: A Questionnaire-Based Survey. <i>Dermatology and Therapy</i> , 2020, 10, 671-680.	3.0	4
36	Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment. <i>British Journal of Dermatology</i> , 2021, 184, 548-550.	1.5	4

#	ARTICLE	IF	CITATIONS
37	Influenza Vaccination in Psoriatic Patientsâ€™ Epidemiology and Patient Perceptions: A German Multicenter Study (Vac-Pso). <i>Vaccines</i> , 2021, 9, 843.	4.4	3
38	Perception and Experience of Biologic Therapy in Atopic Dermatitis: A Qualitative Focus Group Study of Physicians and Patients in Europe and Canada. <i>Dermatology and Therapy</i> , 2021, 11, 2159-2177.	3.0	3
39	Coprevalence of Hidradenitis Suppurativa and Psoriasis: Detailed Demographic, Disease Severity and Comorbidity Pattern. <i>Dermatology</i> , 2021, 237, 759-768.	2.1	3
40	Correct performance of subcutaneous injections in plaque psoriasis: comparison of trained and untrained patients with different application systems in routine clinical care. <i>Journal of Dermatological Treatment</i> , 2020, 32, 1-9.	2.2	0
41	Low Pneumococcal Vaccination among Patients with Psoriasis in Germany: Results from Vac-Pso. <i>Vaccines</i> , 2022, 10, 1005.	4.4	0